Mycotic loads’ determination of non-sterile pharmaceuticals in Lagos state and 16S RDNA identification of the fungal isolates by Oyebanji, Elizabeth Olawumi et al.
16 
 
 
*For Correspondence: olawumioyebanji@gmail.com  
©2018 The authors 
This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, 
distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or 
the publishers. (https://creativecommons.org/licenses/by-nc/4.0/) 
 
Journal of Applied Pharmaceutical Research  
Volume 6, Issue 2, Year of Publication 2018, Page 16 – 28  
DOI: 10.18231/2348-0335.2018.0007 
 
 
Research Article 
JOURNAL OF APPLIED PHARMACEUTICAL RESEARCH | JOAPR 
www.japtronline.com                ISSN: 2348 – 0335 
 
MYCOTIC LOADS’ DETERMINATION OF NON-STERILE 
PHARMACEUTICALS IN LAGOS STATE AND 16S rDNA 
IDENTIFICATION OF THE FUNGAL ISOLATES 
Elizabeth Olawumi Oyebanji
1,2
*, Adedotun Adeyinka Adekunle
1
, Herbert Alexander B. Coker
3
, 
Gboyega Ebenezer Adebami
2
 
 
Article Information  ABSTRACT 
Received: 19th December 2017  Pharmaceuticals are medicinal products used in the prevention, treatment, and diagnosis of 
diseases. As such, the presence of microorganisms’ especially fungal toxins can reduce or 
eliminate the product's therapeutic activity and constitute a potential danger to patient health. 
This study attempts to determine the fungal loads of liquid preparation used as medication in 
Lagos State and its environs and identify the fungal isolates. 252 different types of oral liquid 
drugs (200syrups and 52 suspensions) which included paracetamol syrup, cough syrup and 
antibiotics suspension manufactured in five different pharmaceutical industries in Nigeria were 
methodically sampled and analyzed for fungi contamination using standardized method. The 
isolated fungi were identified using morphological characterization as well as 16SrDNA 
sequencing. 13% of the sampled syrups were found to be contaminated with fungi where 
thecolony forming units for paracetamol syrup, cough syrup and antibiotics suspension ranges 
from 2.0x101 - 9.6×104; 1.0x102- 7.5x104 and 1.0x101- 8.8×104cfu/ml respectively while87% 
yielded no growth.Thirteen (13) morphologically different species of fungi were identified which 
included Aspergillus niger strains, A. tamari strains, A. japonicas, A. flavus, A. awamari, A. 
ellipticus, A. tubingensis, Meyerozyma aaribbica, Candida carpophila and  Eurotiomycetes spp, 
The presence of microorganisms in oral liquid samples might explain the treatment complicacy 
of the diseased children. Therefore, microbiological quality of such drugs is thus suggested.  
Revised: 29th April 2018 
Accepted: 22nd May 2018 
   
Keywords 
Oral drug, Contamination, Fungal load, 
Fungal identification, Colony forming 
unit, Aspergillus 
 
 
_______________________________________________________________________________________________ 
1
Department of Botany, University of Lagos, Nigeria 
2
Department of Biological Sciences, Mountain Top University, Ibafo, Ogun State, Nigeria 
3
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, College of Medicine Campus, Idiaraba, University of Lagos, 
Nigeria 
 
 
 
 
 
 
Journal of Applied Pharmaceutical Research 6 (2); 2018: 16 – 28 Oyebanji et. al  
 
 
  Journal of Applied Pharmaceutical Research (JOAPR)| April – June 2018 | Volume 6 Issue 2 |   17 
INTRODUCTION 
Pharmaceutical drug or medicinal product according to United 
State Food and Drug Administration [1] is any chemical 
substance formulated or compounded as single active 
ingredient which may be in combination with other 
pharmacologically active substance intended for external or 
internal use in the medical diagnosis, to cure, treat or prevent 
diseases. The use of pharmaceutical drug to eradicate an array 
of diseases in human have been in existence for a very 
longtime and the possibility of microbial contamination such as 
viruses, bacteria, fungi and actinomycetes cannot be over 
emphasized due to impaired manufacturing condition [2]. Oral 
liquid preparations have been earmarked as one of the 
pharmaceutical formulations that possess a greater chance of 
microbial contamination than any other drug [3,4] and unless 
they are carefully and tightly closed immediately after opening, 
oral liquid preparations are highly liable to be contaminated by 
air borne bacteria and fungal spores [3]. Moreover, 
microorganisms such as fungi, yeast, bacteria, actinomyces and 
viruses have been found to play a major role in the 
contamination of pharmaceutical products leading to changes 
in the physical characteristics, such asfermentation of syrups, 
breaking of emulsions, thinning of creams, appearance of 
turbidity or deposit, and changes in colour and odour [5, 6]. 
The contamination of the raw materials used for the 
manufacturing of oral drugs with microbes may be associated 
with the unexplained treatment complications been experienced 
in patients [7, 8]. As such, the presence of contaminating 
microflora, especially when it is in excess of the acceptable 
limit of >10cfu/ml in oral drugs, result to a major threat in 
public health measures [9].   
 
The presence of certain fungi especially molds in 
pharmaceuticals are harmful due to the production of 
metabolites that may be toxic to consumers and cause rapid 
deterioration of the product. This invariably results in 
biodegradation of the different components of formulations 
arising from the production of toxins[10,4]. Some fungi genera 
especially Aspergillus and Mucor which have been confirmed 
to produce toxins such as A. flavus, A. parasiticus and A 
turingensis should not be found in pharmaceutical products 
[6].Moreover, some of the dosage forms of oral drugs, if stored 
in favourable environment, can serve as substrates for fungi 
and other microorganisms [11,12]. Mugoyela and Mwambete 
[13] stated that moisture and high amount of sugar in the oral 
liquid drugs in particular, can support the microbial growth. 
Nirmala et al. [14] concluded that improper storage, defects in 
handling, presence of sweetening agents, and reconstitution 
methods of oral liquid drug formulations such as aqueous 
solutions, suspensions, syrups and emulsions used for 
pediatrics are at a greater risk of microbial contamination 
during consumption.  
 
Drug manufacturing industry is one of the dynamically 
growing and expanding production sectors in Nigeria, and the 
quality of medicine available domestically varies significantly 
as they are mostly retail oriented. Adeshina et al. [15] felt that 
an anarchy situation could prevail in the marketing of drugs, 
due to a large number of illegal and unlicensed drug stores 
selling poorly manufactured pharmaceuticals. However, in 
Nigeria, there is paucity of report or research studies on 
microbial load of fungi of finished pharmaceutical products as 
well as the molecular studies on possible fungal isolates 
implicated in pharmaceutical product contamination. 
Therefore, intermittent examination of microbiological quality 
of the pharmaceutical or medicinal products especially non-
sterile preparation consumed mostly by the children is highly 
important for their well-being.  Though the knowledge of these 
according to Hossain, [11] and Moniruzzaman et al. [16] does 
not prove to be sufficient in predicting the safety of the sold 
oral liquid drugs, but contribute significantly in the area of 
prevention.   
  
MATERIALS & METHODS 
Sampling methodology 
Paracetamol syrup, cough syrup and antibiotics were sampled 
from five different pharmaceutical industries; E, F, M, S and V 
located in Lagos State. Samples were collected from 
pharmaceutical shops and directly from the production 
companies. Drug collection was done for two years which was 
limited to products manufactured within one year as shown by 
manufacturers. The pharmaceutical products were collected in 
sterile Ziploc bags from one location to the other. All the 
Ziploc bags used for sampling were methodologically labelled 
with necessary information concerning the product. 
Information such as date of manufacture, expiry date and batch 
number were recorded and transported to the Laboratory under 
aseptic condition in order to minimize environmental exposure. 
All the samples collected have NAFDAC registration numbers 
clearly written on the packs and bottle labels. 
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Culture technique 
The total viable fungiwere estimated using serial dilutions.Pour 
plate method was used from the dilution 10
-1
, 10
-2
, 10
-3
and 10
-
4
of each sample.1ml of dilution was aseptically transferred to 
disposable sterile petri-dishes (15cm diameter at a depth of 
4.0mm). Potato Dextrose Agar (PDA) (Oxoid) (supplemented 
with streptomycin) was used for culturing. The agar was 
sterilised by autoclaving at 121˚C for 15 minutes and allowed 
to cool to approximately 45
o
C before pouringtwenty millilitres 
(20 ml) of the liquefied agarinto each petri-dish. All the plates 
were incubated at 30
o
C for 4 – 7 days. Moreover, plating of 
each sample was done in duplicate and the average values 
obtained were multiplied by the dilution factors to get the total 
colony forming unit per millilitre (cfu/ml) count.For those 
plates that showed growth, re-culturing was carried out three 
months after sampling and a month before expiration of the 
product [17]. 
 
Identification of the Fungal Isolates 
Morphological, biochemical and molecular methods were used 
for the identification of the isolates. The plates were examined 
for the presence of noticeable growth and oncethis is observed, 
the texture, pigmentation and topography of each specific type 
of colony was noted for proper and accurate identification. A 
little portion of the growth colony was teased with an 
inoculating needle and mount on the slide with a drop of 
Lactophenol blue, covered with a cover slip. The preparation 
was examined under a light microscope with an attached 
camera (Motic Mc digital coloured camera) connected to a 
computer for the microscopic photography of the fungi. The 
essence of this was to observe the exact arrangement of the 
conidiophores and the way the spores are produced. The 
identities of these fungi isolates were certified using cultural as 
well as morphological methodologies by comparing the isolates 
with confirmed representatives of different fungalspecies in 
relevant texts before molecular identificationfor proper 
confirmation [18, 19]. 
 
DNA Extraction using modified CTAB protocol 
DNA extraction was done according to the modified method of 
Umesha et al.[20]. Ten millilitre (10ml) of isolation buffer (10x 
CTAB) containing 80µl of mercaptoethanol in 50ml blue cap 
tube was pre-heated in 65°C water bath. One gramme (1g) of 
freshly scrapped pure culture plates of each fungal isolate was 
added to the preheated isolation buffer in each tube. The 
mixture was then incubated at 65°C for 15 minutes. Ten 
millilitres (10ml) of SEVAG (24:1 chloroform: Isoamyl 
alcohol), then mixed gently but thoroughly.  
 
The cap of the tubes containing the mixture was then opened to 
release gas, which was then re-tightened and homogenized 
using an orbital shaker (100rpm) for 60minutes. After rocking, 
the tubes were spinned at 4000rpm and 25°C for 20minutes. 
The mixture gave a clear and colourless aqueous solution at the 
top containing the DNA, which was then removed into another 
set of tubes with the aid of a plastic transfer pipette. Two third 
volume of isopropanol was added to the aqueous solution. The 
mixture was then mixed gently and stored in a freezer at -20°C 
for 24hours in order for the inherent DNA to precipitate. The 
mixture was then spinned in a centrifuge at 3000rpm for 
5minutes, followed by the addition of 3ml of 70% ethanol to 
dislodge the pellet and facilitate washing. The mixture was 
spinned again at 3000rpm for 5minutes, after which the liquid 
was discarded and the alcohol was allowed to evaporate by 
leaving the tubes open on its side. The DNA was re-suspended 
in 1.5ml of water and stored at (-20°C). The samples were run 
on 1% Agarose Gel Electrophoresis to verify the presence of 
DNA in the samples, prior to PCR and DNA sequencing. 
 
DNA Amplification and 16SrDNA Sequence Determination 
of the fungal isolates 
Polymerase Chain Reaction (PCR) assay was performed using 
the method stated byGonzalez-Mendoza et al. [21]. PCR 
amplification reaction was carried out using ITS1 F 
(TCCGTAGGTGAACCTGCGG) and ITS4 R 
(TCCTCCGCTTATTGATATGC) primers. Amplification was 
done in 0.2-ml tube and reaction mixture containing 2.5 µL of 
80–100 ng of genomic DNA, 1 µL of 20 pmol of each primer, 
and 20 µL of Dream Taq Green PCR master mix (Containing: 
0.25 mM each dNTP, 2 mM MgCl2 and Taq DNA 
polymerase).  
 
The PCR was carried out in a master gradient thermal cycler 
(LABNET, NJ, USA). The following conditions were used for 
PCR: initial denaturation was done at 94 °C for 5 min; 30 
cycles of denaturation for 1 min at 94 °C, annealing was 
performed at 52 °C for 1 min, initial extension was done at 
72 °C for 1 min while final extension was carried out at 72 °C 
for 10 min, followed by cooling at 4 °C until the samples were 
recovered. The amplified DNA was confirmed through gel 
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electrophoresis using 1 % agarose gel. The generated sequence 
data from the DNA extraction were sequenced by Inqaba 
Biotechnology, South Africa. The 16SrDNA gene sequences 
obtained were compared with the NCBI database [22]. 
 
RESULTS & DISCUSSIONS  
A total of two hundred and fifty-two (252) samples were 
collected, out of which thirty three samples (33, 13%) showed 
growth while two hundred and twenty samples (220, 87%) did 
not show any noticeable growth on incubation (Fig. 1). The 
colony forming units for Paracetamol syrup, cough syrup and 
antibiotics suspension ranged from 2.0x10
1
-9.6×10
4
; 1.0x10
2
-
7.5x10
4
 and 1.0x10
1
-8.8×10
4
cfu/ml respectively (Table 1a, 1b 
&1c). Paracetamol syrup from Pharmaceutical companies VM, 
VI and EI produced the highest contaminations while FM, MP 
and SM did not showed any noticeable growth at all.  
 
Cough syrups from pharmaceutical company VI produced the 
highest growth on incubation while FM and SMshowed no 
growth. Antibiotics suspensions from production companies 
EM and VI gave the highest contaminations while that of FM 
and SMshowed no appreciable growth (Fig. 1).The thirty three 
(33) samples produced thirteen (13) morphologically different 
species of fungiwhich were identified using cultural, 
morphological and molecular methods.  
 
Figure 2 shows the Electrophorogram of the extracted DNA of 
the thirteen isolates using modified CTAB protocol. BLAST 
(Basic Local Alignment Search Tool) analyses of the 16S 
rDNA genes nucleotide sequences of the fungal strains showed 
a range of  95-99% similarities(with their respective accession 
number)to:A. niger strains A(KJ881377.1), A. niger strains 
B(KF305758.1), A. niger strains C(KF305742.1); A. tamari 
strain A(KP784375.1) and A. tamari strain B(KF221089.1); 
A.japonicas(KC128815.1),A. flavus(KF221065.1), A. 
awamari(KF154413.1), A. ellipticus (EU821329.1)A. 
tubingensis (KC020122.1), Meyerozyma aaribbica 
(KP674752.1), Candida carpophila (KP131683.1) and  
Eurotiomycetes sp. ( JX174154.1)(Fig. 3and 4). Furthermore, 
out of the four fungal genera isolated, the genus Aspergillus 
gave the highest percentage occurrence of 76% while the 
genera Candida, Meyerozyma and Eurotiomycetes gave 8% 
respectively (Fig. 5). 
 
 
Fig. 1: Percentage occurrence of fungi isolates from different Pharmaceutical companies 
Key: E, F, M, S and V indicate pharmaceutical Companies codes. Sub S and P indicate samples collected from pharmaceutical 
shops and production companies respectively. 
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Table 1a: Fungi Load of the Paracetamol Syrups Sampled 
Sampling code Sampling Location TFCIMAS (cfu/ml) TFC3M (cfu/ml) TFCBE (cfu/ml) 
EP(P)1 DF 3.7×10
2
 6.7×10
3
 9.6×10
4
 
EP(P)4 DF 4.0×10
2
 7.1×10
2
 6.5×10
4
 
ES(P)1 PS 4.0×10
2
 4.7×10
3
 6.8×10
4
 
ES(P)5 PS 3.0x10
2
 3.7x10
4
 5.7x10
4
 
MP(P)2 PS 5.0x10
1
 5.7x10
4
 7.5x10
4
 
MP(P)3 DF 4.0x10
1
 4.7x10
2
 5.0x10
4
 
MS(P)2 PS 2.5x10
2
 4.0x10
3
 6.7x10
4
 
VP(P)1 DF 4.0×10
2
 6.0×10
4
 7.6×10
4
 
VP(P)12 DF 2.0x10
1
 3.0x10
2
 4.7x10
4
 
VP(P)13 PS 2.0x10
2
 3.7x10
4
 4.0x10
4
 
VS(P)11 PS 4.0×10
2
 4.4×10
3
 5.1×10
3
 
VS(P)3 PS 4.4×10
2
 3.7×10
4
 5.7×10
4
 
 
Table 1b: Fungi Load of the Cough Syrups Sampled 
Sampling code Sampling Location TFCIMAS (cfu/ml) TFC3M (cfu/ml) TFCBE (cfu/ml) 
EP(C)5 PS 1.0x10
2
 2.5x10
4
 5.0x10
4
 
EP(C)9 DF 2.5x10
2
 3.0x10
4
 5.5x10
4
 
ES(C)12 PS 4.4×10
2
 5.0×10
3
 5.0×10
4
 
ES(C)3 PS 4.0×10
2
 5.4×10
3
 5.4×10
3
 
ES(C)4 DF 3.0x10
1
 5.0x10
4
 6.6x10
4
 
MS(C)13 DF 4.4×10
1
 4.0×10
4
 6.0×10
4
 
VP(C)1 PS 2.2x10
2
 4.4x10
4
 5.4x10
4
 
VP(C)6 PS 3.5x10
2
 4.2x10
4
 5.5x10
4
 
VP(C)8 DF 4.7×10
2
 5.4×10
3
 6.6×10
4
 
VS(C)2 PS 3.2x10
1
 5.5x10
3
 6.0x10
4
 
VS(C)3 PS 4.0x10
2
 5.0x10
3
 7.5x10
4
 
 
Table 1c: Fungi Load of the Antibiotics Suspension Sampled 
Sampling code Sampling Location TFCIMAS (cfu/ml) TFC3M (cfu/ml) TFCBE (cfu/ml) 
EP(A)10 PS 2.0x10
2
 3.7x10
3
 6.7x10
4
 
EP(A)2 PS 1.0x10
1
 3.0x10
3
 6.7x10
4
 
ES(A)4 PS 3.0x10
2
 4.4x10
3
 4.0x10
4
 
ES(A)5 DF 1.0x10
2
 2.5x10
3
 4.0x10
4
 
MP(A)13 DF 3.7×10
2
 6.4×10
3
 8.8×10
4
 
MS(A)3 PS 2.0x10
2
 3.5x10
3
 6.7x10
4
 
VP(A)3 DF 3.7×10
2
 6.3×10
3
 7.8×10
4
 
VP(A)4 DF 4.0×10
2
 7.5×10
3
 8.5×10
4
 
VS(A)2 DF 1.0x10
2
 4.0x10
3
 7.0x10
4
 
VS(A)7 PS 3.7x10
1
 4.4x10
3
 6.0x10
4
 
Key: TFCIMAS=Total fungi count immediately after sampling; TFC3M= Total fungi count 3 months after sampling; TFCBE= Total fungi count 
a month before expiration; DF=Directly from Factory; PS= Pharmaceutical shops; cfu /ml= colony forming unit per ml 
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Fig. 2: Electrophorogram of extracted DNA samples for the 13 morphologically different fungal isolates using modified 
CTAB protocol. EP(P)1, MP(P)2, ES(P)1, VP(P)12, VP(C)1, VP(C)6, VS(C)2, VS(C)3, EP(A)2, ES(A)5, MP(A)13, VS(A)7, 
MS(A)3 respectively 
 
Culture plates of the isolates Photomicrograph of the isolates Characteristics of colonies 
 
 
Colony is a fast growing one, black in 
colour. Conidial head is short. 
Conidiophores is erect, simple with 
thick wall 
Fig. 3a(i): Aspergillus niger strain A Fig. 3a(ii): Aspergillus niger strain A  
 
 
The colony is a fast growing one 
formed in groups, black in colour. 
Conidial head are short. Conidiophores 
is erect, simple with thick walled. 
Fig. 3b(i): Aspergillus niger strain B Fig. 3b(ii): Aspergillus niger  strain B  
 
 
The conidial head are compact with 
phalides borne directly on vesicle.  This 
fungus colony is typically black in 
colour. Conidial heads are long 
columnar and biserated with long and 
thin blue smooth-walled stipes. 
Fig. 3c(i): Aspergillus niger strain C Fig. 3c(ii): Aspergillus nigerstrain C  
1 2 3 4 5 6 7 8 9 10 11 12 13 
1,517bp 
100bp 
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The conidiophores hyaline or pale 
brown erect and simple thick walled. 
The fungus colony is fast growing 
Fig. 3d(i): Aspergillus awamari Fig. 3d(ii): Aspergillus awamari  
  
The conidiophores upright, simple 
terminating in a globose shape with 
spores at the apex and the entire 
surface. The colony is a fast growing 
fungus. 
Fig. 3e(i): Aspergillus tubingensis Fig. 3e(ii): Aspergillus tubingensis  
  
The colony are granular, flat, often with 
radial grooves. Yellow at first but 
quickly becoming bright to green with 
time. Conidial head are typically 
radiate, later splitting to form loose 
columns, having heads with phalides. 
Fig. 3f(i): Aspergillus flavus Fig. 3f(ii): Aspergillus flavus  
  
It is a fast growing fungus. The fungus 
colony is typically black in colour 
.These colonies range in size from a 
single mold spore to acres across 
conidial heads are short columnar and 
uniserate with short, and black smooth-
walled stipes. 
Fig. 3g(i): Aspergillus japonicus Fig. 3g(ii): Aspergillus japonicus  
  
The fungus is fast growing. Black in 
colour. Conidiophore is erect with 
smooth stipe wall. 
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Fig. 3h(i): Aspergillus ellipticus Fig. 3h(ii): Aspergillus ellipticus  
  
The fungus colony is typically suede-
like and buffy to sand brown in 
colouration. The conidial heads are 
short columnar and biseriates, with 
short, brownish and smooth-walled 
stipes. 
Fig. 3i(i): Aspergillus tamari A Fig. 3i(ii): Aspergillus tamari A  
  
The fungus colony is typically black in 
colour. The conidial heads are short 
columnar and uniserate with short, and 
black smooth-walled stipes. 
Fig. 3j(i): Aspergillus tamari strain B Fig. 3j(ii): Aspergillus tamari strain B  
  
The fungal colony is a slow growing 
one. It is singly arranged having a 
whitish cream colour. It produces  tiny 
spores that are scattered on the surface 
Fig. 3k(i): Candida carpophila Fig. 3k(ii): Candida carpophila  
  
The fungus colony is typically black in 
colour. The conidial heads are short 
columnar and uniserates with short and 
black smooth-walled stipes. 
Fig. 3l(i): Eurotiomycetes sp. Fig. 3l(ii): Eurotiomycetes sp.  
  
It is a fast growing fungus. The colony 
is a flat, moist-smooth and cream to 
grey green in colour. It produces 
clusters of small blastospores along the 
pseudohyphae. 
Fig. 3m(i): Meyerozyma caaribbica Fig. 3m(ii): Meyerozyma caaribbica  
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Fig. 4. Molecular Phylogenetic analysis by Maximum Likelihood method of the isolates 
 
Fig. 5: Percentage occurrence of different fungi genera isolated. With Aspergillus having 76.9% occurrence while Candida, 
Eurotiomycetes and Meyerozyma have 7.7% respectively 
Non-sterile liquid drugsare characterized by their viscous 
consistency and sweet taste with active medicaments. Theses 
pharmaceutical syrups constitute the most convenient dosage 
for babies, children and adult [23]. The deleterious effect of 
ingesting microbiologically contaminated non-sterile 
pharmaceutical is more significant as the patients involved are 
already diseased. As such, it is very important to carry out all 
round examination on the potency of these drugs before useas 
medication especially in babies and little children.Mahboob et 
al. [24] and Emejuru et al. [25],observed that the addition of 
high amount of sweetening agent as well as preservatives could 
enhance mycotic growth in pharmaceutical products.The World 
Health Organization (W.H.O), European Pharmacopoeia 
(EP),United States Pharmacopoeia (USP), and other recognized 
regulatory agencieshave guidelines to ascertain the quality 
assurance of pharmaceutical products [26]. National Agency 
Aspergillus Candida Eurotiomycetes Meyerozyma
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for Food and Drug Administration and Control (NAFDAC), the 
body assigned with the responsibility of monitoring the quality 
assurance of consumable food items including pharmaceutical 
products in Nigeria, published a handbook in 2000 [27], where 
the standard microbiological specifications for the certification 
of syrup oral suspensions are well outlined. Thus, it was 
typically stated that total viable fungal counts must not exceed 
1.0x10
2
CFU/ml which is far below the observed mycotic loads 
in some of the analyzed samples. The European Directorate for 
the Quality of Medicines & HealthCare [28] as well as United 
State Pharmacopoeia [9] standards for the Total Yeast and 
Mould Count (TYMC) for the assessment of the 
microbiological quality of non-sterile pharmaceutical is 
10
2
cfu/ml or cfu/g which is in line with NAFDAC standard 
[29, 30]. Furthermore, high contaminations of the sampled 
antibiotics from our study were not unexpected as the drug is 
formulated to inhibit the growth of bacterial infections and not 
necessarily fungi. Emejuru et a l[25] reported a fungal growth 
in 16 out of the 24 selected oral liquid pharmaceuticals in 
Southeastern geopolitical zone of Nigeria. Gad et al.[6] 
observeda range of 10
1
 - 10
3 
cfu/ml contamination of the 
paediatrics drugs he sampled from Egyptian market with very 
high prevalence of major fungi genera.Moreover, the observed 
high fungal loadsfrom this work were similar to the findingsof 
Al-Kafet al. [31] on his research on microbial and 
physicochemical assays of paracetamol in different brands of 
analgesic and antipyretic syrups sold in Sana'a City of Yemen. 
However, Khanom et al. [32] who carried out microbiological 
analysis of liquid oral drugs available in Bangladesh, 
contradicted this finding where his total fungal count of the oral 
suspensions were found to be in the range of 10
1
 to 10
2
.Fatema 
et al. [33]report on the assessment of microbiological quality of 
the pediatric oral liquid drugs in Dhaka city, Bangladesh, was 
similar to our finding. He observed that fungi presence were 
not significant during the initial assessment of sampling, 
however, most of the samples were found to support fungal 
growth after 21 days with the CFU ranging from 10
1
 – 
10
3
which is similar to our finding. 
 
As observed from this study, Aspergillus accounts for about 
70% of the total fungal isolates (Fig. 4). The genus Aspergillus 
is one of the most well researched fungi genera and more than 
180 officially recognized species have been identified which 
included 20 human pathogens as well as beneficial strains used 
in the production of foodstuffs and important industrial 
enzymes [34]. In particular, the genera Candida, Rhodotorula, 
Penicillium,Aspergillus, Rhizopus, Alternaria, and Mucor have 
been reported to be a great contaminant of pharmaceutical 
products especially syrup, suspension and cosmetics materials 
[35]. Moreover, Elmorsy and Hafez, [36] observed that fungal 
isolates from cosmetic preparation were 30% Aspergillus spp., 
30%Rhizopus spp., 18% Candida spp., 15% Trichoderma spp.. 
and 7% Penicillium spp. Timberlake and Marshall [37] 
described Aspergilli as ubiquitous group of filamentous fungi 
which have been in existence for over 200 million years witha 
great impact onhuman health and society. Atkinson and Brojer, 
[38] described the ubiquitous nature of Aspergillus has been 
due to their saprophytic feeding habit as well as their ability to 
grow in a wide range of temperatures. Mugoyela et al. [13] 
noted that the presence of potentially pathogenic opportunistic 
microbes especially Aspergillus in pharmaceutical drugs cannot 
be overemphasized because of their significancein the 
deterioration of the health status of patients particularly infants 
with an immature immune system and immune-compromised 
individuals. Furthermore, the species of Aspergillus frequently 
isolated include A. fumigatus, A. flavus, A. nidulans, A. niger 
and A. terreus[38]. Aspergillus has beenidentified as the 
causative agent of Aspergillosis infection which is a non-
contagious disease that affect humans, mammals and mostly 
wild or domestic birds [39].Perfect et al.[40] categorized the 
various Aspergillus infections as: invasive aspergillosis, 
chronic necrotizing aspergillosis, allergic broncho-pulmonary 
aspergillosis and fungus ball or aspergilloma. Wattier and 
Ramirez-Avila, [41]identified A. fumigatus and A. flavus as one 
of the causative agent of  Invasive Aspergillosis (IA)which 
happened to be one of the most common and serious infectious 
complications occurring in immune-compromised patients. 
 
The presence of moulds in any pharmaceutical products 
especially consumables like syrup and suspension should be 
considered as harmful since they produce metabolites that may 
be toxic to consumers. Gad et al. [6],Wu et al. [42] and 
Ratajczak et al. [35] reported that moulds and some species of 
Aspergillus such as A. flavus and A. parasiticus can produce 
mycotoxins which can be carcinogenic and mutagenic in 
nature. Furthermore, they emphasized that these mycotoxins 
can cause allergies, acute and chronic poisoning, liver damage, 
and diseases of the respiratory and digestive systems. Raw 
materials, ingredients, water supply, unhygienic environmental 
condition and lack of aseptic handling has been identified as 
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major factors that can significantly contribute to high microbial 
growth in pharmaceutical products [43, 44]. In developing 
countries like Nigeria, the possibility of disease incidence is 
very high due to poor hygienic practices, consumption of 
contaminated food and water, and unstable environmental 
condition due to pollution [45]. These give room for the 
infectious and virulent nature of opportunistic pathogens when 
resistance mechanisms are impaired either by severe 
underlying disease or by use of immunosuppressive drugs [46]. 
 
CONCLUSION 
The finding from this research shows that fungal loads are 
present in some of pharmaceutical products sampled in the 
quantities that are not acceptable according to the standard 
provided by local (Nigeria) and international drug regulatory 
bodies. Some of the isolated fungi may not be pathogenic but 
their presence can interfere with the functionality of the drug 
through biodegradation of the active component of such syrup. 
Fungi are also known to produce toxins which can be 
carcinogenic in nature, as such their presence in any pediatrics’ 
drug should not be taken lightly. Usually most patients are 
potentially immune compromised when they are taking drugs 
which accelerate the chances of diseases acquired by 
opportunistic pathogens. Therefore, the presence of any 
microorganism should be considered undesirable for all drugs. 
The compliance sector in Nigeria’s Pharmaceuticals should 
strictly deal with microbial stringency within the 
manufacturing which should include packaging, distribution 
and storage of pharmaceutical products, added preservatives, 
sweeteners, and production environment. Furthermore, 
microbial loads of non-sterile pharmaceuticals can be reduced 
to barest minimum by preventing the possibility of spoilage 
organisms and by adding well-researched antimicrobial agents 
orchemical preservatives. Unhygienic environmental condition 
coupled with improperhandling of raw materials, ingredients 
and products must also be checked. Finally, good 
manufacturing practice is non-negotiable and must be strictly 
adhere to at all times if the microbial contamination is to be 
totally eradicated. 
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